Literature DB >> 8109927

Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro.

M S Alcouloumre1, M A Ghannoum, A S Ibrahim, M E Selsted, J E Edwards.   

Abstract

Defensin NP-1, derived from the neutrophils of rabbits, was tested for its fungistatic and fungicidal activity against strains of Cryptococcus neoformans. The MICs for the encapsulated strains tested ranged from 3.75 to 15.0 micrograms of NP-1 per ml. The minimum fungicidal concentrations for these strains were similar to the MICs. An acapsular strain, however, had a lower MIC of 0.93 and minimum fungicidal concentration of 1.88 micrograms/ml. NP-1 demonstrated time-dependent and concentration-dependent killing of C. neoformans. Killing occurred rapidly in the first 20 min of exposure to NP-1 and was maximum at 90 to 120 min. Killing of C. neoformans by NP-1 was concentration dependent with 31% +/- 9% survival at 25 micrograms/ml, 13% +/- 4% survival at 50 micrograms/ml, 9% +/- 5% survival at 75 micrograms/ml, and 5% +/- 3% survival at 100 micrograms/ml. NP-1's fungicidal effect on C. neoformans was also inoculum dependent, with increased activity observed at 10(4) versus 10(5) or 10(6) cells per ml. In addition, stationary-phase C. neoformans was less susceptible to NP-1 killing than yeast cells in the logarithmic phase. Subinhibitory concentrations of both NP-1 (0.25 x MIC) and fluconazole (0.25 x MIC) acted synergistically in inhibiting growth of C. neoformans. Similar combinations of NP-1 and amphotericin B, however, did not yield synergy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8109927      PMCID: PMC192760          DOI: 10.1128/AAC.37.12.2628

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Determination of the disulfide array in the human defensin HNP-2. A covalently cyclized peptide.

Authors:  M E Selsted; S S Harwig
Journal:  J Biol Chem       Date:  1989-03-05       Impact factor: 5.157

2.  Purification, primary structure, and antimicrobial activities of a guinea pig neutrophil defensin.

Authors:  M E Selsted; S S Harwig
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

3.  Primary structures of three human neutrophil defensins.

Authors:  M E Selsted; S S Harwig; T Ganz; J W Schilling; R I Lehrer
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

4.  Purification and antimicrobial properties of three defensins from rat neutrophils.

Authors:  P B Eisenhauer; S S Harwig; D Szklarek; T Ganz; M E Selsted; R I Lehrer
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

5.  Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity.

Authors:  R I Lehrer; A Barton; K A Daher; S S Harwig; T Ganz; M E Selsted
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

6.  Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis.

Authors:  A M Stamm; R B Diasio; W E Dismukes; S Shadomy; G A Cloud; C A Bowles; G H Karam; A Espinel-Ingroff
Journal:  Am J Med       Date:  1987-08       Impact factor: 4.965

7.  Modulation of the in vitro candidacidal activity of human neutrophil defensins by target cell metabolism and divalent cations.

Authors:  R I Lehrer; T Ganz; D Szklarek; M E Selsted
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

8.  Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide.

Authors:  D L Granger; J R Perfect; D T Durack
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

9.  Defensins. Natural peptide antibiotics of human neutrophils.

Authors:  T Ganz; M E Selsted; D Szklarek; S S Harwig; K Daher; D F Bainton; R I Lehrer
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

Review 10.  Cryptococcosis.

Authors:  J R Perfect
Journal:  Infect Dis Clin North Am       Date:  1989-03       Impact factor: 5.982

View more
  13 in total

Review 1.  Antifungal peptides: novel therapeutic compounds against emerging pathogens.

Authors:  A J De Lucca; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 2.  Host immunity to Cryptococcus neoformans.

Authors:  Soma Rohatgi; Liise-Anne Pirofski
Journal:  Future Microbiol       Date:  2015       Impact factor: 3.165

3.  Characterization of a fish antimicrobial peptide: gene expression, subcellular localization, and spectrum of activity.

Authors:  A M Cole; R O Darouiche; D Legarda; N Connell; G Diamond
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

4.  Peptide-based Antifungal Therapies against Emerging Infections.

Authors:  A Matejuk; Q Leng; M D Begum; M C Woodle; P Scaria; S-T Chou; A J Mixson
Journal:  Drugs Future       Date:  2010-03       Impact factor: 0.148

5.  Human neutrophil-mediated nonoxidative antifungal activity against Cryptococcus neoformans.

Authors:  S S Mambula; E R Simons; R Hastey; M E Selsted; S M Levitz
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

6.  Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds.

Authors:  Calliandra Maria de-Souza-Silva; Fernanda Guilhelmelli; Daniel Zamith-Miranda; Marco Antônio de Oliveira; Joshua Daniel Nosanchuk; Ildinete Silva-Pereira; Patrícia Albuquerque
Journal:  J Vis Exp       Date:  2018-02-14       Impact factor: 1.355

7.  The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis.

Authors:  Mark J Mannis
Journal:  Trans Am Ophthalmol Soc       Date:  2002

8.  Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival.

Authors:  Oscar Zaragoza; Cara J Chrisman; Maria Victoria Castelli; Susana Frases; Manuel Cuenca-Estrella; Juan Luis Rodríguez-Tudela; Arturo Casadevall
Journal:  Cell Microbiol       Date:  2008-06-28       Impact factor: 3.715

9.  Morphology of defensin-treated Staphylococcus aureus.

Authors:  M Shimoda; K Ohki; Y Shimamoto; O Kohashi
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

10.  Role of sphingomyelin synthase in controlling the antimicrobial activity of neutrophils against Cryptococcus neoformans.

Authors:  Asfia Qureshi; Marimuthu Subathra; Angus Grey; Kevin Schey; Maurizio Del Poeta; Chiara Luberto
Journal:  PLoS One       Date:  2010-12-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.